Nonspecific effects of oral vaccination with live-attenuated Salmonella Typhi strain Ty21a.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101653440 Publication Model: eCollection Cited Medium: Internet ISSN: 2375-2548 (Electronic) Linking ISSN: 23752548 NLM ISO Abbreviation: Sci Adv Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : American Association for the Advancement of Science, [2015]-
    • Subject Terms:
      Vaccination*; Polysaccharides, Bacterial/*immunology ; Salmonella typhi/*immunology ; Typhoid Fever/*prevention & control ; Typhoid-Paratyphoid Vaccines/*immunology ; Vaccines, Attenuated/*immunology; Administration, Oral ; Adult ; CD4-Positive T-Lymphocytes/immunology ; CD4-Positive T-Lymphocytes/metabolism ; Cytokines/metabolism ; Female ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Monocytes/immunology ; Monocytes/metabolism ; Polysaccharides, Bacterial/administration & dosage ; Typhoid Fever/immunology ; Typhoid Fever/metabolism ; Typhoid-Paratyphoid Vaccines/administration & dosage ; Vaccines, Attenuated/administration & dosage ; Young Adult
    • Abstract:
      Epidemiological and immunological evidence suggests that some vaccines can reduce all-cause mortality through nonspecific changes made to innate immune cells. Here, we present the first data to describe the nonspecific immunological impact of oral vaccination with live-attenuated Salmonella Typhi strain Ty21a. We vaccinated healthy adults with Ty21a and assessed aspects of innate and adaptive immunity over the course of 6 months. Changes to monocyte phenotype/function were observed for at least 3 months. Changes to innate and adaptive immune cell cytokine production in response to stimulation with vaccine and unrelated nonvaccine antigens were observed over the 6-month study period. The changes that we have observed could influence susceptibility to infection through altered immune responses mounted to subsequently encountered pathogens. These changes could influence all-cause mortality.
    • References:
      Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10085-90. (PMID: 27528682)
      Arch Dis Child. 2017 Nov;102(11):1077-1081. (PMID: 28501809)
      J Biol Chem. 2005 Jan 14;280(2):1336-45. (PMID: 15485828)
      Trends Immunol. 2013 Sep;34(9):431-9. (PMID: 23680130)
      Vaccine. 2016 Aug 31;34(38):4586-4593. (PMID: 27491688)
      BMJ. 2010 Nov 30;341:c6495. (PMID: 21118875)
      Immunity. 2014 Sep 18;41(3):478-492. (PMID: 25220212)
      Nat Immunol. 2015 Oct;16(10):1034-43. (PMID: 26322480)
      Trans R Soc Trop Med Hyg. 2016 Sep;110(9):527-533. (PMID: 27738283)
      Wkly Epidemiol Rec. 2014 May 23;89(21):221-36. (PMID: 24864348)
      J Infect Dis. 1992 Aug;166(2):451-2. (PMID: 1634818)
      J Glob Health. 2012 Jun;2(1):010401. (PMID: 23198130)
      J Immunol. 2012 Dec 15;189(12):5503-7. (PMID: 23150714)
      Oncoimmunology. 2015 May 22;4(7):e1016697. (PMID: 26140240)
      Nature. 2007 Jun 21;447(7147):972-8. (PMID: 17538624)
      BMJ. 2016 Oct 13;355:i5170. (PMID: 27737834)
      Trans R Soc Trop Med Hyg. 2016 Dec;110(10):570-581. (PMID: 27856947)
      Clin Infect Dis. 2013 Jul;57(2):283-9. (PMID: 23572484)
      Immunity. 2013 Jan 24;38(1):79-91. (PMID: 23273845)
      Cell Host Microbe. 2018 Jan 10;23(1):89-100.e5. (PMID: 29324233)
      Infect Immun. 2003 Dec;71(12):6808-19. (PMID: 14638767)
      Clin Infect Dis. 2015 Nov 15;61(10):1504-11. (PMID: 26219694)
      mBio. 2018 Feb 20;9(1):. (PMID: 29463654)
      Lancet. 2016 Mar 12;387(10023):1054-1055. (PMID: 27025182)
      Vaccine. 2014 Feb 19;32(9):1055-60. (PMID: 24440210)
      Viruses. 2013 Aug 28;5(9):2062-78. (PMID: 23989890)
      Science. 2014 Sep 26;345(6204):1251086. (PMID: 25258085)
      PLoS Negl Trop Dis. 2015 Jun 11;9(6):e0003837. (PMID: 26065687)
      J Innate Immun. 2014;6(2):152-8. (PMID: 24192057)
      Pediatr Infect Dis J. 2007 Mar;26(3):247-52. (PMID: 17484223)
      Front Microbiol. 2018 Jan 31;9:83. (PMID: 29445364)
      Vaccine. 2015 Jun 19;33 Suppl 3:C36-41. (PMID: 25902362)
      J Exp Med. 1998 Feb 2;187(3):307-17. (PMID: 9449711)
      Nat Genet. 2016 Oct;48(10):1211-1217. (PMID: 27548315)
      Mol Immunol. 2008 Aug;45(13):3671-81. (PMID: 18541300)
      Clin Infect Dis. 2015 Jun 1;60(11):1611-9. (PMID: 25725054)
      PLoS One. 2016 May 10;11(5):e0154656. (PMID: 27164006)
      Bioinformatics. 2008 Jun 1;24(11):1403-5. (PMID: 18397895)
      Nat Med. 2007 Jul;13(7):843-50. (PMID: 17558415)
      Nat Immunol. 2014 Oct;15(10):895-9. (PMID: 25232810)
      Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17537-42. (PMID: 22988082)
      Vaccine. 2018 Jul 25;36(31):4725-4733. (PMID: 29958737)
      Nat Rev Immunol. 2016 Jun;16(6):392-400. (PMID: 27157064)
      J Infect Dis. 2016 Jun 1;213(11):1809-19. (PMID: 26810369)
      Vaccine. 2013 Oct 1;31(42):4874-80. (PMID: 23916987)
    • Grant Information:
      United Kingdom Wellcome Trust; MR/M011569/1 United Kingdom MRC_ Medical Research Council
    • Accession Number:
      0 (Cytokines)
      0 (Polysaccharides, Bacterial)
      0 (Ty21a typhoid vaccine)
      0 (Typhoid-Paratyphoid Vaccines)
      0 (Vaccines, Attenuated)
    • Publication Date:
      Date Created: 20190302 Date Completed: 20200409 Latest Revision: 20220129
    • Publication Date:
      20240829
    • Accession Number:
      PMC6392763
    • Accession Number:
      10.1126/sciadv.aau6849
    • Accession Number:
      30820452